Thus, ER+ breast cancer cells refractory to palbociclib can be regulated in the in vitro and in vivo experimental models [90]; this may explain why some ER+ breast cancer subjects who progress during a specific CDK4/6i then might become sensitive to another CDK4/6i. Here, CDK4 is linked to breast cancer.